메뉴 건너뛰기




Volumn 26, Issue 1, 2000, Pages 47-50

Narrowing the gap: Access to HIV treatments in developing countries. A pharmaceutical company's perspective

Author keywords

Access to medicines; AIDS; Developing countries; Glaxo Wellcome; Public health; Treatment gap

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; ZIDOVUDINE;

EID: 0033995098     PISSN: 03066800     EISSN: None     Source Type: Journal    
DOI: 10.1136/jme.26.1.47     Document Type: Short Survey
Times cited : (8)

References (16)
  • 1
    • 0005233291 scopus 로고    scopus 로고
    • HAART reduces overall costs of HIV care at DVAMC-Denver
    • February, abstract 200
    • See, for example:McCollum, M, et al HAART reduces overall costs of HIV care at DVAMC-Denver. Fifth Conference on Retroviruses and Opportunistic Infections. February, 1998: abstract 200: 116.
    • (1998) Fifth Conference on Retroviruses and Opportunistic Infections , pp. 116
    • McCollum, M.1
  • 2
    • 0343332212 scopus 로고    scopus 로고
    • Joint United Nations Programme on HIV/AIDS (UNAIDS). AIDS Epidemic update: December 1998. Geneva: UNAIDS
    • Joint United Nations Programme on HIV/AIDS (UNAIDS). AIDS Epidemic update: December 1998. Geneva: UNAIDS, 1998. (www.unaids.org/highband/document/epidemio/ wadr98e/pdf)
    • (1998)
  • 3
    • 0029128834 scopus 로고    scopus 로고
    • Success rates for new drugs entering clinical testing in the United States
    • DiMasi JA. Success rates for new drugs entering clinical testing in the United States. Clinical Pharmacology and Therapeutics 1905;58:1-14, and: Office of Technology and Assessment. Pharmaceutical R&D: costs, risks and rewards (OTA-H-523). Washington DC: US Government Printing Office, 1996.
    • (1905) Clinical Pharmacology and Therapeutics , vol.58 , pp. 1-14
    • DiMasi, J.A.1
  • 4
    • 0029128834 scopus 로고    scopus 로고
    • Washington DC: US Government Printing Office
    • DiMasi JA. Success rates for new drugs entering clinical testing in the United States. Clinical Pharmacology and Therapeutics 1905;58:1-14, and: Office of Technology and Assessment. Pharmaceutical R&D: costs, risks and rewards (OTA-H-523). Washington DC: US Government Printing Office, 1996.
    • (1996) Pharmaceutical R&D: Costs, Risks and Rewards (OTA-H-523)
  • 6
    • 0033528527 scopus 로고    scopus 로고
    • Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Cote d'Ivoire: A randomised trial
    • Wiktor SZ, Ekpini E, Karon JM, Nkengasong J, Maurice C, Severin ST. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Cote d'Ivoire: a randomised trial. Lancet 1999; 353:781-5.
    • (1999) Lancet , vol.353 , pp. 781-785
    • Wiktor, S.Z.1    Ekpini, E.2    Karon, J.M.3    Nkengasong, J.4    Maurice, C.5    Severin, S.T.6
  • 7
    • 0033528521 scopus 로고    scopus 로고
    • Six-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Cote d'Ivoire and Burkino Faso: A double-blind placebo-controlled multicentre trial
    • Dabis F, Msellati P, Meda N, Welffens-Ekra C, You B, Manigart O. Six-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Cote d'Ivoire and Burkino Faso: a double-blind placebo-controlled multicentre trial. Lancet 1999; 353:768-92.
    • (1999) Lancet , vol.353 , pp. 768-792
    • Dabis, F.1    Msellati, P.2    Meda, N.3    Welffens-Ekra, C.4    You, B.5    Manigart, O.6
  • 8
    • 0033523454 scopus 로고    scopus 로고
    • Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda.HIVNET 012 randomised trial
    • Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda.HIVNET 012 randomised trial. Lancet 1999;354:795-802.
    • (1999) Lancet , vol.354 , pp. 795-802
    • Guay, L.A.1    Musoke, P.2    Fleming, T.3    Bagenda, D.4    Allen, M.5    Nakabiito, C.6
  • 10
    • 0003111077 scopus 로고    scopus 로고
    • Interim analysis of early efficacy of three short ZDV/3TC combination regimens to prevent mother-to-child transmission of HIV-1: The PETRA trial
    • Jan-Feb abstract S7
    • Saba J. Interim analysis of early efficacy of three short ZDV/3TC combination regimens to prevent mother-to-child transmission of HIV-1: the PETRA trial. Sixth Conference on Retroviruses and Opportunistic infections, Jan-Feb 1999; abstract S7.
    • (1999) Sixth Conference on Retroviruses and Opportunistic Infections
    • Saba, J.1
  • 12
    • 0032558333 scopus 로고    scopus 로고
    • International multicentre pooled analysis of late postnatal mother-to-child transmission of HIV-1 infection
    • For data on late postnatal transmission see also Leroy V, et al. International multicentre pooled analysis of late postnatal mother-to-child transmission of HIV-1 infection. Lancet 1998; 352:597-600.
    • (1998) Lancet , vol.352 , pp. 597-600
    • Leroy, V.1
  • 14
    • 0003530162 scopus 로고
    • Investing in health. Washington DC: World Bank
    • World Bank. World development report 1993. Investing in health. Washington DC: World Bank, 1993, and: World Health Organisation. Investing in health research and development. Report of the ad hoc committee on health research related to future intervention options. Geneva: World Health Organisation, 1996.
    • (1993) World Development Report 1993
  • 16
    • 34548194623 scopus 로고    scopus 로고
    • A positive response to perinatal HIV
    • See, for example: Anonymous [editorial]. A positive response to perinatal HIV. Lancet 1999;353:511.
    • (1999) Lancet , vol.353 , pp. 511


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.